Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer

Licata, Luca; Mariani, Marco Giovanni; Rossari, Federico; Viale, Giulia; Notini, Giulia; Naldini, Matteo Maria; Bosi, Carlo; Piras, Marta M.; Dugo, Matteo

doi:10.1016/j.breast.2023.03.014

Cited by 6 publications

(4 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies have reported no correlation between PD-L1 expression in tumor tissues and CTCs in NSCLC [28,30,34], urothelial carcinoma [26], and breast cancer [35]. These clinical results support the notion that PD-L1 expression in cancer cells is a heterogeneous and dynamic biomarker that varies spatially and temporally [36,37]. As PD-L1 expression varies between primary and metastatic sites and even within tumor nests, PD-L1 expression analysis of CTCs is considered a useful tool to complement this heterogeneity [34].…”

Section: Discussionmentioning

confidence: 54%

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

Nosaka,

Murata,

Akazawa

et al. 2024

Cancers

View full text Add to dashboard Cite

There remains no reliable biomarker of therapeutic efficacy in hepatocellular carcinoma (HCC) for the PD-L1 inhibitor atezolizumab and bevacizumab (Atezo/Bev). Circulating tumor cells (CTCs) enable the serial collection of living tumor cells. Pre-treatment and serial CTC gene expression changes and tumor histology were evaluated to identify predictors of response to Atezo/Bev. Peripheral blood from 22 patients with HCC treated with Atezo/Bev and 24 patients treated with lenvatinib was serially collected. The RNA expression in CTCs was analyzed using qRT-PCR. Higher PD-L1 expression in pre-treatment CTCs was associated with response and improved prognosis with Atezo/Bev treatment, but not with lenvatinib. There was no correlation between PD-L1 expression in CTCs and that in liver tumor biopsy specimens scored using imaging software. Furthermore, PD-L1 RNA expression in CTCs was dynamically altered by Atezo/Bev, decreasing during effective response and increasing upon progression. CTC-derived RNA collected during Atezo/Bev indicates that patients with higher PD-L1 expression in CTCs at baseline were 3.9 times more responsive to treatment. Therefore, PD-L1 RNA levels in CTCs are an accurate response predictor and may be a monitorable biomarker that changes dynamically to reflect the response during Atezo/Bev treatment.

show abstract

Section: Discussionmentioning

confidence: 54%

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

Nosaka,

Murata,

Akazawa

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“… 74 Therefore, tissue biopsy no longer satisfies the clinical need for tumor trait detection. 75 , 76 …”

Section: Liquid Biopsy For Cancer Screeningmentioning

confidence: 99%

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

Wang,

Zhang,

Zhang

et al. 2024

MedComm

View full text Add to dashboard Cite

Currently, tumor treatment modalities such as immunotherapy and targeted therapy have more stringent requirements for obtaining tumor growth information and require more accurate and easy‐to‐operate tumor information detection methods. Compared with traditional tissue biopsy, liquid biopsy is a novel, minimally invasive, real‐time detection tool for detecting information directly or indirectly released by tumors in human body fluids, which is more suitable for the requirements of new tumor treatment modalities. Liquid biopsy has not been widely used in clinical practice, and there are fewer reviews of related clinical applications. This review summarizes the clinical applications of liquid biopsy components (e.g., circulating tumor cells, circulating tumor DNA, extracellular vesicles, etc.) in tumorigenesis and progression. This includes the development process and detection techniques of liquid biopsies, early screening of tumors, tumor growth detection, and guiding therapeutic strategies (liquid biopsy‐based personalized medicine and prediction of treatment response). Finally, the current challenges and future directions for clinical applications of liquid biopsy are proposed. In sum, this review will inspire more researchers to use liquid biopsy technology to promote the realization of individualized therapy, improve the efficacy of tumor therapy, and provide better therapeutic options for tumor patients.

show abstract

“…Biopsy techniques are known to affect the accuracy of assessment of PD-L1 + cells, thus affecting patient stratification ( 39 – 42 ). Constrained sampling space also limits the clinical extrapolation and generalizability of results derived from biopsies ( 43 , 44 ). Thirdly, in most clinical scenarios, it is impossible to obtain consecutive biopsies during the course of ICB therapies.…”

Section: Introductionmentioning

confidence: 99%

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment

Luo,

Wang,

Mai

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) therapies, that is, using monoclonal antibodies to reinvigorate tumor-reactive, antigen-specific T cells from the inhibitory effects of CTLA-4, PD-1 and PD-L1 immune checkpoints, have revolutionized the therapeutic landscape of modern oncology. However, only a subset of patients can benefit from the ICB therapy. Biomarkers associated with ICB response, resistance and prognosis have been subjected to intensive research in the past decade. Early studies focused on the analysis of tumor specimens and their residing microenvironment. However, biopsies can be challenging to obtain in clinical practice, and do not reflect the dynamic changes of immunological parameters during the ICB therapy. Recent studies have investigated profiles of antigen-specific T cells derived from the peripheral compartment using multi-omics approaches. By tracking the clonotype and diversity of tumor-reactive T cell receptor repertoire, these studies collectively establish that de novo priming of antigen-specific T cells in peripheral blood occurs throughout the course of ICB, whereas preexisting T cells prior to ICB are exhausted to various degrees. Here, we review what is known about ICB-induced T cell phenotypic and functional changes in cancer patients both within the tumor microenvironment and in the peripheral compartment. A better understanding of parameters influencing the response to ICBs will provide rationales for developing novel diagnostics and combinatorial therapeutic strategies to maximize the clinical efficacies of ICB therapies.

show abstract

Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer

Cited by 6 publications

References 129 publications

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment

Contact Info

Product

Resources

About